Lonza Group AG (LONN.VX)

LONN.VX on Virt-X Level 1

106.90CHF
11:31am EDT
Price Change (% chg)

CHF0.90 (+0.85%)
Prev Close
CHF106.00
Open
CHF105.60
Day's High
CHF107.40
Day's Low
CHF104.60
Volume
226,571
Avg. Vol
201,449
52-wk High
CHF118.60
52-wk Low
CHF76.75

LONN.VX

Chart for LONN.VX

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 1.38
Market Cap (Mil.): CHF5,609.54
Shares Outstanding (Mil.): 52.92
Dividend: 2.15
Yield (%): 2.03

Financials

  LONN.VX Industry Sector
P/E (TTM): 29.68 21.24 134.82
EPS (TTM): 3.57 -- --
ROI: 3.26 3.90 15.46
ROE: 8.81 5.60 17.82
Search Stocks

Lonza courts biotech backers to shore up outsourcing contracts

ZURICH - Swiss drugs industry supplier Lonza Group AG is courting the financial backers of biotech firms to help secure a steady stream of projects and offset some of the volatility of outsourced production contracts, a senior executive said.

22 Aug 2014

Lonza courts biotech backers to shore up outsourcing contracts

ZURICH, Aug 22 - Swiss drugs industry supplier Lonza Group AG is courting the financial backers of biotech firms to help secure a steady stream of projects and offset some of the volatility of outsourced production contracts, a senior executive said.

22 Aug 2014

UPDATE 2-Lonza profit boosted by drug production outsourcing

* Shares up 5.8 pct (Recasts with share price, adds analyst)

24 Jul 2014

Lonza shares rise 3.3 pct after H1 results

ZURICH, July 24 - Lonza shares rise 3.3 pct at the open on Thursday after first-half net profit more than trebled. (Reporting by Joshua Franklin)

24 Jul 2014

Lonza confirms full-year outlook

ZURICH, April 24 - Life science and specialty chemicals group Lonza confirmed its outlook for the full year after its business performance improved in the first quarter from the year-ago period.

24 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks